摘要
目的：探讨头孢哌酮/他唑巴坦药品不良反应（ADR）发生的一般特点与规律，并提出预防对策，为促进临床安全、有效、合理用药提供参考。方法采用回顾性研究方法，对我院2005年1月～2015年5月上报至国家不良反应监测中心的76例头孢哌酮/他唑巴坦 ADR 报告，从患者年龄、性别、原患疾病、用法用量、ADR 发生时间、ADR 临床表现等方面进行回顾性统计分析。结果76例头孢哌酮/他唑巴坦 ADR 报告中，患者在性别方面无统计学差异（P＞0.05），而在年龄、原患疾病等方面存在显著差异性（P＜0.01）。ADR 发生的时间以30 min内为主（59.21%）。ADR 以皮肤及其附件损害最多（55.22%），其次是全身性损害、血液系统损害等。76例中严重的 ADR 有7例，主要以过敏性休克和血液系统损害为主。结论临床应严格掌握头孢哌酮/他唑巴坦的适应证及用法用量，加强对头孢哌酮/他唑巴坦的用药监护，告知患者使用该药可能发生的 ADR，并做好突发严重 ADR 的应急处理措施。
Objective To summarize the characteristics and rules of adverse drug reactions （ADRs） induced by cefoperazone/tazobactam and provide prevention countermeasures for clinical safe, effective and rational use of antimicrobials by analysis of antibacterial-related ADR reports. Methods 76 ADR reports were statistically analyzed from Jan, 2005 to May, 2015 in our hospital to ADR monitoring center. The patient＇s age, gender, diseases, usage and dosage, ADR occurrence time and clinical manifestations were analyzed retrospectively. Results Among the 76 cases of ADR, the difference in gender aspect was not significant （P 〉0.05）. There were statistically significant differences of the age, kinds of diseases （P 〈0.01）. Less than 30 minutes after administration were ADR high -incidence period （59.21%）. The main side effects were injuries of skin and its appendages （55.22%）, and followed by systemic damage and hematological system damage, etc. 76 cases of ADR including 7 reports of serious adverse reactions, allergic shock and hematological system were involved in the most of cases. Conclusion The indication and dosage of cefoperazone/tazobactam should be strictly mastered by clinicians, and the pharmaceutical care of cefoperazone/tazobactam should be strengthened. The medical staff should tell patients potential ADR and prepare the emergency treatment measures for incidentally critical ADR.
出处
《中国药物警戒》
2015年第10期623-626,631,共5页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金资助项目(81403031)
